ARTICLE | Politics & Policy
Former OND leader Jenkins joins Greenleaf
February 2, 2017 11:35 PM UTC
John Jenkins joined regulatory consultancy Greenleaf Health Inc. (Washington, D.C.) as a principal for drug and biological products. In January, Jenkins resigned as director of the Office of New Drugs at FDA’s Center for Drug Evaluation and Research.
During his 15 years directing OND, Jenkins led the transformation of the agency into the world's most efficient reviewer of new drugs. He created and managed systems that ensure FDA's compliance with PDUFA commitments, including review action goals (see BioCentury, Jan. 2)...